Skip to main content
OpenTrials
Completed

NCT Number: NCT02567929

Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer

Anesthetics agents has variety inflammation during the cancer surgery. This perioperative inflammation can influence to cancer metastasis or recurrence.

The purpose of this study is to prove the variation of immune cell activity between preoperative and postoperative period.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

20 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Konkuk University Medical Center

Seoul, 143-729, South Korea

About this study

The patients were allocated randomly to receive propofol or sevoflurane. Also, a total of 18ml of blood sample was obtained for total 3 times in consecutive order.

  • immediate before anesthesia induction
  • postoperative 1 hours
  • postoperative 24 hours

Serum in blood will be obtained and activity of helper T cell, natural killer cell and level of serum cytokine will be evaluated by flow cytometry or enzyme-linked immunosorbent assay

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patient who was planned to undergo colon cancer surgery.

Exclusion criteria

  • age < 20 years old
  • history of hypersensitivity reaction in propofol or sevoflurane
  • history of previous cancer
  • patient with ongoing inflammation

Treatment and study plan

Propofol group

Drug

Patient will be anesthetized by using propofol infusion during operation.

Other names: propofol

Sevoflurane group

Drug

Patient will be anesthetized by using sevoflurane inhalation during operation.

Other names: sevoflurane

Primary outcomes

  1. CD39 and CD73 on circulating regualtory T cells

    Time frame: preoperative time. postoperative 1 hours and 24 hours

    change of percentage of CD39 and CD73 (scores range from 0 to 100)

Secondary outcomes

  1. Circulating natural killer cells

    Time frame: preoperative time. postoperative 1 hours and 24 hours

    change of percentage of circulating natural killer cell (scores range from 0 to 100)

Other outcomes

  1. Circulating type 1 and type 17 helper T cells

    Time frame: preoperative time. postoperative 1 hours and 24 hours

    change of percentage of helper T cell (scores range from 0 to 100)

Sponsors and collaborators

Lead sponsor

Konkuk University Medical Center

Other

Registry information

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Oct 5, 2015
Registry last updated
Apr 2, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.